NYSE:FERG
NYSE:FERGTrade Distributors

Evaluating Ferguson After 34% Rally and Strong Q2 Earnings Momentum in 2025

Thinking about making a move with Ferguson Enterprises? You are not alone. With shares recently closing at $232.49, Ferguson has been quietly making waves while many investors debate whether the stock is now a buy, a hold, or due for a breather. Over the past year, it has gained 9.7%, which is not a headline-grabbing surge but steady enough to catch the eye. Even more compelling, the stock is up 34.1% year-to-date and a substantial 110.1% over three years, reflecting solid long-term momentum...
NasdaqCM:GXAI
NasdaqCM:GXAIEntertainment

This "Triple Threat" AI Company Just Dropped a Game-Changing Product

Jolt_Communications
Gaxos.ai (NASDAQ: GXAI), the small but ambitious AI company, has just unveiled a new weapon in its arsenal: Art-Gen.AI. While many investors know Gaxos for its dual focus on AI in gaming and health, this new platform catapults the company into the booming world of generative content creation, a market projected to reach hundreds of billions in annual revenue.
NasdaqGS:RPRX
NasdaqGS:RPRXPharmaceuticals

Royalty Pharma (RPRX) Acquires US$885 Million Royalty Interest In Amgen's Imdelltra

Royalty Pharma (RPRX) recently acquired a royalty interest in Amgen's Imdelltra, a move that may have added confidence to investors, contributing to the company's 11% share price increase over the last quarter. This acquisition, along with its royalty sharing arrangements and the drug's anticipated market success, illustrates Royalty Pharma’s strategic business expansion. Concurrently, it saw enhancements in its board composition with new appointments, which might have played a beneficial...